Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
MEDICAL AND PEDIATRIC ONCOLOGY 1998;
30:117-21. [PMID:
9403021 DOI:
10.1002/(sici)1096-911x(199802)30:2<117::aid-mpo9>3.0.co;2-l]
[Citation(s) in RCA: 39] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE
To determine whether pamidronate is a safe and effective agent for the treatment of severe hypercalcemia of malignancy in children.
MATERIALS AND METHODS
A retrospective review of the charts of five children treated with pamidronate 1-2 mg/kg for severe, refractory hypercalcemia of malignancy. All children failed conventional therapy. Statistical analysis was done utilizing the two-tailed Student's t-test.
RESULTS
All five children had complete resolution of their hypercalcemia in a predictable pattern within 24-48 hours. The average decrease in serum calcium was 1.63 mmol/L (6.54 mg/dl). (P < .01) The adverse effects were mild and transient, and consisted of hypocalcemia, hypophosphatemia, and hypomagnesemia.
CONCLUSIONS
Pamidronate at a dose of 1 mg/kg is a safe and effective treatment for severe, refractory hypercalcemia of malignancy in children.
Collapse